Presentations Will Highlight Corporate and Clinical Progress HOUSTON , Sept. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced its participation at two upcoming

Webcast presentation scheduled for Tuesday, September 1, 2020 HOUSTON , Aug. 27, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc . (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its Chief Executive

Company Closes $6.2M Public Offering and Expands Clinical Program to Include Ewing-Related Sarcomas Conference Call and Live Audio Webcast Scheduled for Today, August 12, 2020 , at 4:30 p.m. ET HOUSTON , Aug. 12, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals , Inc. (Nasdaq: SLRX), a

Conference Call and Live Audio Webcast Scheduled for Wednesday, August 12, at 4:30 p.m. ET HOUSTON , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc.  (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, announced that the

New Patent Protects Composition of Matter and Methods of Use Through At Least August 2032 HOUSTON , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced the

HOUSTON , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. . (Nasdaq: SLRX) today announced the closing of its previously announced underwritten public offering of 5,130,390 shares of its common stock, including 669,181 shares sold pursuant to the exercise in full of the

HOUSTON , July 30, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced the pricing of an underwritten public offering of 4,461,209 shares of its common stock at a price to

HOUSTON , July 29, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced that it has commenced an underwritten public offering of shares of its common stock.

Pre-Clinical Data and Early Clinical Observations Support Company’s Decision to Research Seclidemstat as a Potential Treatment in Ewing-Related Sarcomas HOUSTON , July 29, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical stage oncology company targeting cancers

New Facilities Include Dedicated Laboratory Space for Preclinical Research HOUSTON , July 28, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced that it has relocated its